Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2308MR)

This product GTTS-WQ2308MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2308MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8795MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ14038MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ8471MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ14678MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ8749MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ2427MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ12713MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ7408MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW